Eli Lilly & Company (NYSE:LLY) ranks among the best high growth high margin stocks to buy now. Deutsche Bank retained its Buy rating and $1,200 price target for Eli Lilly & Company on February 4, citing the pharmaceutical giant’s strong fiscal year 2026 projections.
Eli Lilly & Company posted revenues of around $19.3 billion in the fourth quarter of 2025, exceeding Street projections of $18 billion, thanks mostly to strong results from its diabetes and obesity drugs Mounjaro and Zepbound.
The company announced fiscal year 2026 revenue forecast of $80-$83 billion and non-GAAP EPS forecasts of $33.50-$35.00 per share, beating the analyst average projections of $78 billion in revenue and $33.09 per share.
Eli Lilly & Company further confirmed the introduction of Orforg in the US in Q2 2026 as well as the implementation of Medicare’s obesity coverage on July 1, 2027, in addition to the submission of Orforg’s European file for Type 2 diabetes.
Eli Lilly & Company is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
